A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)-Reference-Cited by-同舟云学术

A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO)

Published:2016-11-28 Issue:3 Volume:143 Page:541-550
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Sehouli Jalid,Tomè Oliver,Dimitrova Desislava,Camara Oumar,Runnebaum Ingo Bernhard,Tessen Hans Werner,Rautenberg Beate,Chekerov Radoslav,Muallem Mustafa Zelal,Lux Michael Patrick,Trarbach Tanja,Gitsch Gerald

Funder

North-Eastern German Society of Gynecological Oncology (NOGGO)

MEDAC GmbH

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00432-016-2307-0.pdf

Reference20 articles.

1. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al (2012) OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 30:2039–2045. doi: 10.1200/JCO.2012.42.0505

2. Boztug H, Zecca M, Sykora K-W, Veys P, Lankester A, Slatter M et al (2014) Treosulfan-based conditioning regimens for allogeneic HSCT in children with acute lymphoblastic leukaemia. Ann Hematol. doi: 10.1007/s00277-014-2196-8